The Effect of Canagliflozin Dose on Renal and Cardiovascular Outcomes in Type 2 Diabetes and High Cardiovascular Risk
Abstract
Introduction: Pharmacokinetic data suggest a potential dose-dependent effect of sodium-glucose co-transporter-2 (SGLT-2) inhibitors on surrogate markers of efficacy, but the impact of SGLT-2 inhibitor dose on renal and cardiovascular outcomes remains uncertain.
Methods: In this post hoc analysis, we evaluated the efficacy and safety of two canagliflozin doses (100 and 300 mg) on hard clinical endpoints using participant-level data from the CANVAS randomised controlled trial (4330 patients). The primary outcome was a composite of doubling of serum creatinine, renal failure, or death due to renal cause. Secondary outcomes included a composite cardiovascular endpoint; hospitalisation for heart failure; all-cause mortality; and progression or regression of albuminuria. Safety outcomes included serious hyperkalaemia and acute kidney injury. Cox proportional hazards models were used.
Results: There was no significant difference in the composite renal endpoint between the two doses: hazard ratio (HR) 0.85; 95% confidence interval (CI) 0.38-1.89 (p = 0.68). Both doses, however, were associated with significant reductions in the incidence of the primary renal endpoint compared with placebo: HR 0.49 (95% CI 0.25-0.95; p = 0.03) for 100 mg and HR 0.41 (95% CI 0.20-0.83; p = 0.01) for 300 mg. There was no difference between the two doses of the drug in any of the secondary endpoints. Importantly, no added safety concerns were identified with either dose.
Conclusions: In this post hoc…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 4,330 participants or records.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.